Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

2-Weekly CHOP Chemotherapy With Dose-Dense Rituximab for the Treatment of Patients Aged 61 to 80 Years With Aggressive CD-20 Positive B-Cell Lymphomas: A Phase-II/Pharmacokinetic Study (CHOP-R-ESC)

NCT00290667 is registered in ClinicalTrials.gov with German High-Grade Non-Hodgkin's Lymphoma Study Group as lead sponsor.

NCT NCT00290667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00290667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
2-Weekly CHOP Chemotherapy With Dose-Dense Rituximab for the Treatment of Patients Aged 61 to 80 Years With Aggressive CD-20 Positive B-Cell Lymphomas: A Phase-II/Pharmacokinetic Study (CHOP-R-ESC)
Lead sponsor
German High-Grade Non-Hodgkin's Lymphoma Study Group
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2004
Completion date
November 30, 2015
Enrollment
586 (actual)
Sites
338

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma